Reaction Biology Corp. ("RBC") was founded to pursue new economies in HTS and biochemical assays. RBC offers outsourced screening, profiling, and assay development, at lower cost than traditional outsourcing labs. RBC also performs NIH-funded research in technology development and early stage drug discovery. Screening partnerships with industry partners are also part of the RBC portfolio.

RBC specializes in developing new nanoliter scale assaying methods. By carefully scaling down enzyme and compound volume RBC is able to offer outsourced biochemical assays at a much more economical price than other outsource or even in-house labs.

RBC's scientists have specifically studied the effects of miniaturization on standard assays, and have selected the latest technology to maintain high levels of repeatability and low error rates.

RBC utilizes a proprietary suite of techniques in its low volume well based assays. In addition, RBC performs NIH funded research on its DiscoveryDot™ microarray platform. DiscoveryDot™ uses a patent pending chemical archiving method, together with a unique spray deposition technique, to reduce compound volumes to the nanoliter scale. Learn more about DiscoveryDot™ here.

Management

Haiching Ma – Chief Technology Officer
Kurumi Horiuchi – Director of Biochemistry
Kerri Flanagan – Accounting Manager
Yuan Wang – Lab Manager
Cindy Spadaro – Administration and HR
Matt Oristano – President

Board

Matt Oristano – Chairman
Mr. Oristano is President of Alda Inc, a private investment firm. In addition, he serves on the board of USA Mobility Inc. (Nasdaq: USMO) and its audit committee. He is also on the board of Crystalplex Corporation. From 1993 to 1999, Mr. Oristano was Chairman and CEO of People's Choice TV Corp, a public wireless TV and internet company, which he founded in 1988 and sold to Sprint in 1999. Mr. Oristano has a degree in physics from Rennselaer Polytechnic Institute.

Tom Petzinger, Jr.
Mr. Petzinger is CEO of LaunchCyte, a biotechnology development firm. Mr. Petzinger also serves as Chairman of Immunetrics Inc., Proteopure Inc., and Knopp Neurosciences. Mr. Petzinger co-founded LaunchCyte following 22 years as a reporter and editor at The Wall Street Journal, where he covered technology entrepreneurship. He is a director of the Pennsylvania Biotechnology Association and author of three best-selling books.

Michael Kramer
Mr. Kramer is a Partner of Perella Weinberg Partners. Prior to selling his firm Kramer Capital Partners to Perella Weinberg, Mr. Kramer was the head of Financial Restructuring and a member of the Management Committee at Greenhill & Co. Prior to Greenhill, Mr. Kramer was the co-head of the eastern region of Houlihan Lokey Howard & Zukin and ran the Mergers and Acquisitions and Financial Restructuring businesses. Additionally, Mr. Kramer was actively involved in the founding and development of Houlihan Lokey’s merchant banking business.

Jon Kaufman, PhD
Dr. Kaufman played a key role in the creation of Reaction Biology in his former capacity as CSO of LaunchCyte, where he originated university licensing opportunities. Dr. Kaufman is also a director of Crystalplex Corp. Dr. Kaufman has worked in bioinformatics at SmithKline Beecham and in project management at Merck. He received his doctorate in biochemistry and molecular biophysics from the University of Pennsylvania, where he worked in the Center for Technology Transfer. Dr. Kaufman received his MBA in Finance from the Wharton School.

Scott Diamond, PhD
Dr. Diamond is the scientific founder of RBC. He is the director of the Penn Center for Molecular Discovery. He received his bachelor’s degree in chemical engineering in 1986 from Cornell University and his Ph.D. from Rice University in 1990. He holds the Arthur E. Humphrey Chair of Chemical and Biomolecular Engineering.

Scientific Advisors

Scott Diamond, PhD
Dr. Diamond is the director of the Penn Center for Molecular Discovery. He received his bachelor’s degree in chemical engineering in 1986 from Cornell University and his Ph.D. from Rice University in 1990. He holds the Arthur E. Humphrey Chair of Chemical and Biomolecular Engineering. Dr. Diamond researches biotechnologies in several key areas: endothelial mechanobiology, blood clot dissolving therapies, blood coagulation, nonviral gene therapy, proteomics, and high throughput drug discovery. He has produced over 80 publications and patents and has served on advisory committees to NSF, NIH, AHA, and NASA, and has consulted extensively for industry and government. Diamond is the recipient of the NSF National Young Investigator Award, the NIH FIRST Award, the American Heart Association Established Investigator Award, and the Allan P. Colburn Award, the highest distinction given by the American Institute for Chemical Engineering for publication accomplishment by a member under the age of 35. Currently, Dr. Diamond is the Director of the Penn Biotechnology Masters Program, one of the largest in the country with more than 130 students. Dr. Diamond also serves as Associate Director of the Institute for Medicine and Engineering (IME).

Haiching Ma – Chief Technology Officer, Reaction Biology Corporation

John McCall, PhD
Dr. McCall is the President of PharMac LLC, and a Senior Consultant in areas of drug discovery, project management, project evaluation, and research organization. He chairs an NINDS (National Institute of Neurological Disorders and Stroke) Development Team investigating new therapies for spinal muscular atrophy, and is a member of nine scientific advisory boards. He has over 50 patents and 55 journal publications. Previously he was Vice President of Pfizer Global Research and Development and a member of the Pfizer Global Technology Board. At Pharmacia Dr. McCall was Global Vice President of Discovery Chemistry with responsibility for Structural and Analytical Chemistry, Medicinal and Combinatorial Chemistry, Computational Chemistry, Cheminformatics, and managed a global staff of 570.